‘Stable’ Indian Pharma Outlook Seen Despite Challenges
This article was originally published in PharmAsia News
One-year returns for investors in the Bombay Stock Exchange's Healthcare index may be down over 13%, but in what may bring some comfort to shareholders, the outlook for India’s pharmaceutical companies is "stable," according to an independent credit rating agency. This is despite a string of problems ranging from tighter US generic competition to intensifying regulatory scrutiny to emerging market currency volatility.
Register for our free email digests: